# A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors

> **NCT06826313** · PHASE1 · RECRUITING · sponsor: **Guangzhou Virotech Pharmaceutical Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **BIOLOGICAL:** VRT106

## Key facts

- **NCT ID:** NCT06826313
- **Lead sponsor:** Guangzhou Virotech Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-19
- **Primary completion:** 2025-12-30
- **Final completion:** 2027-03-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06826313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06826313, "A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06826313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*